CD274 and lung cancer: In lung cancer, molecular indicators such as tumor PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), and the presence of tumor-infiltrating immune cells are utilized to assess susceptibility to PD-(L)1 inhibitors [8–10].